Cagrilintide (10mg)

A single-component research material supplied for controlled research environments. Suitable for studies involving peptide characterization and method development in model systems.

Composition

• Cagrilintide
• Appearance: Lyophilized powder in a sealed research vial

Research Focus (non-clinical)

• Peptide identity and purity assessment via HPLC/LC-MS
• Assay development and calibration for quantitative analysis
• Chromatographic method optimization for impurity profiling
• Stability characterization of a lyophilized peptide under laboratory storage conditions

For qualified research professionals and institutional laboratories. Not for human use.

Documentation & Quality Assurance

Each lot is sourced through our verified global supply chain with emphasis on traceability and quality control. We work diligently to obtain and maintain third-party analytical reports (HPLC/LC-MS) and Certificates of Analysis for each batch, as part of our ongoing quality process. These documents are reviewed internally and displayed as they become available. Independent third-party testing is also performed on select lots to confirm identity, purity, and alignment with our internal specifications.

Important Notice

This product is intended for laboratory research use only. It is not intended for human or veterinary use, and must not be used for diagnostic, therapeutic, or clinical purposes.
This material is not a drug, medical device, or dietary supplement, and has not been evaluated by the U.S. Food and Drug Administration.

Quality & Manufacturing

All materials are sourced from carefully vetted domestic and international manufacturing partners who follow quality systems consistent with ISO and cGMP principles. Each supplier is reviewed for reliability, documentation integrity, and transparency in testing.

We require a verified purity of 99% or higher and perform independent third-party spot testing to confirm that select lots meet our internal standards for identity, purity, and composition. Where available, endotoxin testing results are included on Certificates of Analysis to verify laboratory purity; their inclusion is for research quality assessment only and does not imply suitability for human or veterinary use.

All research materials are sealed for integrity and packaged for stability during storage and transport from manufacturing through final delivery.

What It Is

Cagrilintide (AM833) is a stable, lipidated, long-acting synthetic analogue of human amylin, N-terminally acylated with a γGlu linker and a C20 fatty diacid moiety, carrying helix-stabilizing substitutions that form an intramolecular E14–R17 ionic lock stabilizing its N-terminal α-helix along with three amino acid substitutions relative to pramlintide (N14E, V17R, P37Y), and reported to have a plasma half-life of approximately 180 hours.

Research Background

Cagrilintide has been characterized in a range of pre-clinical and clinical research settings. In vitro pharmacological studies employing HEK293 and COS-7 cell transfection systems and cAMP response-element (CRE) reporter assays in BHK cells compared cagrilintide's activity across 25 endpoints against reference ligands including pramlintide, salmon calcitonin, and human calcitonin. Structural investigation using cryo-electron microscopy resolved cagrilintide–receptor complexes at resolutions of approximately 2.2–3.0 Å, complemented by molecular dynamics simulations of two receptor complexes (cagrilintide-bound and rat-amylin-bound AMY3R–Gαs), each modeled in triplicate for a combined total of 6 microseconds. In vivo experiments have been conducted in rodent models, including high-fat-diet-fed wild-type mice and RAMP1/3 double-knockout mice, and the compound has also advanced to Phase 1 and Phase 2 human clinical trials as documented in the published literature.

Observed Areas of Interest in Research

Researchers have investigated cagrilintide as a non-selective agonist at calcitonin receptor (CTR) and amylin receptor (AMYR) heterodimers — specifically AMY1R (CTR+RAMP1), AMY2R (CTR+RAMP2), and AMY3R (CTR+RAMP3). Structural and dynamic studies have documented that cagrilintide adopts a predominantly "bypass" conformation (~85% of cryo-EM particles) at CTR, distinct from the mixed bypass/CT-like conformational equilibrium observed with rat amylin, and that the E14–R17 salt bridge energetically stabilizes this binding mode; the P37 C-terminal substitution further drives differential conformational outcomes depending on which RAMP partner is engaged. Animal studies using RAMP1/3 knockout mice have investigated the role of AMY1R and AMY3R in mediating neuronal activation, assessed via cFos immunostaining, in the area postrema, nucleus of the solitary tract, and lateral parabrachial nucleus — brain regions implicated in energy balance signaling — finding that cagrilintide-induced cFos activation in these dorsal vagal complex regions was markedly reduced or absent in double-knockout animals. Bulk RNA-sequencing of brain tissue in these models has further examined gene expression associated with RAMP1/3 subunit function, with enrichment of terms related to synaptic functionality and vesicle-mediated transport.

Research Notes

Purity verified by third-party laboratory analysis (Certificate of Analysis available on request). Supplied strictly for in-vitro and laboratory research use only. Not for human consumption.

All information above is provided for research and educational reference only and summarizes findings from published scientific literature (predominantly in-vitro and animal models). It does not describe outcomes in humans. This product is not a drug, dietary supplement, or article intended for human or veterinary use.

All products from Blitz Health are manufactured using a lyophilization (freeze-drying) process. This method is designed to maintain product integrity and allows vials to remain stable during shipping for approximately 3–4 months.

Once a vial is reconstituted with bacteriostatic water, it should be stored in the refrigerator to help maintain stability. Under these conditions, reconstituted material is generally considered stable for up to 30 days.

Lyophilization is a dehydration technique in which compounds are frozen and then exposed to low pressure. This causes the water in the vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure. This powder can be kept at room temperature until reconstitution.

Upon receipt, products should be stored away from heat and light. For short-term use, refrigeration at approximately 4°C (39°F) is suitable. For long-term storage (several months to years), vials may be placed in a freezer at approximately -80°C (-112°F). Freezing is the preferred method for preserving product stability over extended periods.

⚠️ Important Notice:
These products are intended for research use only. Not for human consumption.